Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

ABSTRACT:

Objective

In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer was more common in the finasteride group. However, it remains to be determined whether finasteride concentrations may affect prostate cancer risk. In this study, we examined the association between serum finasteride concentrations and the risk of prostate cancer in the treatment arm of the PCPT and determined factors involved in modifying drug concentrations.

Methods

Data for this nested case-control study are from the PCPT. Cases were drawn from men with biopsy-proven prostate cancer and matched controls. Finasteride concentrations were measured using a liquid chromatography-mass spectrometry validated assay. The associatio

SUBMITTER: Chau CH 

PROVIDER: S-EPMC4425512 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature